A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Summary
The purpose of this phase I trial is to evaluate the safety of LGK974 with or without PDR001 in patients with selected solid malignancies, including pancreatic cancer, for whom no effective standard treatment is available.
General Information
NCT#: NCT01351103
Study ID: CLGK974X2101
Trial Phase: Phase I
Trial Sponsor: Novartis Pharmaceuticals
Therapies Used in This Trial: LGK974, Spartalizumab